Netflix has given an eight-episode order to a comedy series from Natasha Lyonne, Amy Poehler and Leslye Headland.The untitled Universal Television project stars Lyonne as Nadia, a young woman who is the guest of honor at an apparently inescapable New York City party.Lyonne co-created the series with Poehler and Headland (“Bridesmaid”), who are all executive producing. Headland is penning the first episode, while Lyonne and Headland are writers on the series.Also Read: Animated Comedy From Amy Poehler in the Works at FoxPoehler‘s Paper Kite Productions, JAX Media and 3 Arts Entertainment are producing with Universal. Paper Kite’s Brooke Posch and 3 Arts’ Dave Becky are executive producing.
NYS Entity Status
NYS Filing Date
JANUARY 29, 2014
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2014 - PAPER KITE CORPORATION
Around the Web
- Amy Poehler Comedy Set at Netflix With Natasha Lyonne to Star
By Ryan Gajewski, provided by
- Wednesday Sep 20, 2017
- NY Times needs to come clean on wiretap headline
By John Crudele - Thursday Sep 7, 2017
The Justice Department announced this week that there was no evidence that Trump Tower was wiretapped, as President Trump alleged. OK, that almost settles the issue. I’m still waiting for the New York Times — the self-proclaimed “paper of record” — to explain its Jan. 20 front page story that had the headline “Wiretapped Data...
- NY's Hometown Paper Once Again Owned By Chicago Publisher
Tuesday Sep 5, 2017
New York's hometown paper is once again owned by a Chicago-based newspaper holding company, following the 'New York Daily News' sale on Monday to Tronc Inc. In a way, it's like deja vu. Tronc wasformerly Tribune Publishing, the publisher of the 'Chicago Tribune,' which originally created the 'New York Daily News' nearly a century ago.
- Gilead Makes Long-Awaited Splash With $12B Bet on Kite, Cell Therapy
By Ben Fidler - Monday Aug 28, 2017
Investors have been waiting for years for Gilead Sciences to make another big splash. This morning, it finally did, agreeing to buy Kite Pharma for close to $12 billion in a significant bet on the success of an emerging, cutting edge type of cancer immunotherapy known as CAR-T. Gilead (NASDAQ: GILD), of Foster City, CA, […]
- Bio Roundup: Kite’s CAR-T Approved, Obamacare Fix & Lilly mRNA Deal
By Frank Vinluan - Friday Oct 20, 2017
Kite Pharma wasn’t expecting a regulatory decision for its non-Hodgkin lymphoma treatment until November, but this week, the company got the FDA’s O.K. The approval of axicabtagene ciloleucel (Yescarta) marks the second time in the two months that the FDA has given the nod to a CAR-T therapy, a treatment made from a patient’s own […]